News & Events

News, industry insights and noteworthy events.

At Tanner, we take pride in the success of our partnerships and acknowledge the milestones achieved in pursuing our mission; to improve lives by increasing access to medicines around the world.

For media or press inquiries, please email us.

Contact Us

All Articles

  1. Tanner Pharma Group Announces New EVP of Technical Operations

    CHARLOTTE, N.C.–(BUSINESS WIRE)–Tanner Pharma Group (“Tanner”), a global pharma-solutions provider, today announced the hiring of Lee Holmes as Executive Vice President of Technical Operations. Having worked in the healthcare industry for over 25 years across a wide range of global leadership roles, Lee brings with him a wealth of industry knowledge and experience, offering particularly…

    Read More
  2. Alimera Sciences and Tanner Pharma Group Initiate Global Named Patient Program for ILUVIEN®

    July 30, 2021 08:00 AM Irish Standard Time DUBLIN, Ireland and CHARLOTTE, USA – Alimera Sciences Europe Limited (“Alimera”), a wholly owned subsidiary of Alimera Sciences, Inc., and Tanner Pharma UK Limited (“Tanner”) announced today the initiation of a global Named Patient Program for ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg for the treatment of…

    Read More
  3. Tanner Pharma Group Gives Donation to Benefit MAP International’s Bringing Children Health Program

    Brunswick, GA, July 30, 2021 – MAP International, a nonprofit health organization whose mission is to provide medicines and health supplies to those in need around the world so that they might experience life to the fullest, recently received a generous donation from Tanner Pharma Group. The donation of over 18,000 units of pharmaceutical products…

    Read More
  4. Building a Culture of Well-Being: A Partnership Between Tanner Pharma Group and Red Dot 365

    At Tanner Pharma, our purpose revolves around people. This focus not only includes the patients, physicians, pharma companies and NGO’s we serve and partner with, but our outstanding team members who help us make a difference and positively impact lives around the world. With that in mind, we are continuously seeking ways to support our…

    Read More
  5. Evolving for the Greater Good in the COVID-19 Era

    At Tanner, we think of giving not only as a duty but as a privilege. A critical part of our success is that the mission and culture of Tanner Pharma is embodied in each member of our team. Whether it’s through the global programs we develop and manage for our clients, or the fundraising we…

    Read More
  6. From Patient Access to Real World Data – Early Access Programs Offer Compelling Results

    What is an EAP? Early Access Programs (EAPs), also referred to as Compassionate Use, Managed Access Programs or Expanded Access Programs, are a pathway by which pharma and biopharmaceutical companies provide investigational new drugs (INDs) to patients with serious conditions. Often, patients have exhausted their approved therapies and cannot participate in a clinical trial. These…

    Read More
  7. Again Life Italia Announces Partnership with Tanner Pharma Group

    CHARLOTTE, N.C., May 27, 2021 — Again Life Italia S.r.l. (“ALI”), a pharmaceutical biotechnology company headquartered in Italy, and TannerLAC UK Limited (“TannerLAC”), a wholly owned subsidiary of Tanner Pharma Group and company leader in the Latin American market, announced today the signing of a business partnership agreement for Latin America.  With a presence in…

    Read More
  8. 5 Things to Consider When Commercializing a New Drug in Latin America

    Some of the over 8,000 drugs in development are poised to be breakthrough treatments that will substantially improve or save patients’ lives. The pharmaceutical companies developing these revolutionary medications have at least two goals: ensuring their research investment is profitable and making sure the drug is available to help any person who needs it.   If your company is developing a new drug, you may be ready to achieve these goals in your existing or developed markets, but what about new ones, like Latin America and other emerging markets? If you haven’t done it before, that’s an entirely…

    Read More
  9. The Value of Real-World Data from Global Expanded Access Programs for Rare Diseases

    John Lagus, Tanner’s EVP of Business Development focusing on managed access programs, recently spoke at MarketandMarkets’ Digital Event on Orphan Drugs and Rare Diseases about the value of real-world data (RWD) from expanded access programs (EAPs) for rare diseases. Here are a few highlights from his talk.  Years ago, while in Botswana, John Lagus met a woman who offered her life savings to purchase critical medicine for her daughter. This conversation stayed with…

    Read More
  10. 3 Insights for Effective Comparator Sourcing

    Whether you’re a global pharma or a biotech start-up, every clinical trial will entail overcoming challenges with sourcing, packaging, and the logistics of clinical materials. Choosing the right partner provides you with flexibility and risk mitigation, ensuring you can choose the most cost-effective solution, and avoid delays. Here are some of the key factors to…

    Read More
  11. Increasing Access for Rare Disease Patients Globally

    Patients who suffer from rare diseases often lack access to innovative treatment options because the manufacturer of the medicine cannot justify the investment in registering and commercializing the medicine in countries where patient populations are low.  Managed Access Programs provide  manufacturers of innovative medicines for rare diseases a cost-effective option to provide patients access in countries where the medicine is not commercially available.  If a physician chooses to prescribe such…

    Read More
  12. Tanner Pharma Group Signs a Distribution Agreement for Partner Therapeutics’ Product, Leukine®

    For Immediate Release Contact: Lindsey Stevens Tanner Pharma Group 704-552-8407 CHARLOTTE, N.C. – Tanner Pharma Group, a global provider of integrated specialty access solutions, has announced the signing of a distribution agreement with Partner Therapeutics, Inc. (PTx), an integrated biopharmaceutical company. The agreement names Tanner Pharma Group as a distributor of Leukine® (sargramostim) in…

    Read More
  13. Tanner Pharma Group to Attend Pharmagora, PQMD, CPhI, US GCSG, and Asembia Conferences

    For Immediate Release Contact: Lindsey Stevens Tanner Pharma Group 704-552-8407 CHARLOTTE, N.C. – Key directors from Tanner Pharma Group (“Tanner Pharma”), a Charlotte-based global pharmaceutical services company, will attend several healthcare conferences throughout the upcoming month of April. The team will join other global executives for the following events:  Pharmagora | April 7th…

    Read More
  14. Tanner Pharma Group To Attend Upcoming CPHI Worldwide Conference

    For Immediate Release Contact: Lindsey Stevens Tanner Pharma Group 704-552-8407 CHARLOTTE, N.C. – Top executives from Tanner Pharma Group (“Tanner Pharma”), a Charlotte-based global pharmaceutical services company, will attend the CPhI Worldwide event on October 24 – 26 in Messe Frankfurt, Germany. Tanner Pharma leverages more than 15 years of pharma services experience to…

    Read More
  15. The Max Foundation and Tanner Pharma Partner on Innovative Drug Distribution Model

    For Immediate Release Contact: Lindsey Stevens Tanner Pharma Group 704-552-8407 Seattle, W.A. – The Max Foundation, an international non-governmental organization dedicated to increasing global access to treatment, care, and support for people living with cancer, and Tanner Pharma Group, a global pharma services company that specializes in patient access to critical medication, have partnered…

    Read More
  16. Proveca and Tanner Pharma initiate global Managed Access Program for Sialanar®

    For Immediate Release Contact: Lindsey Stevens Tanner Pharma Group 704-552-8407 CHARLOTTE, N.C. – Tanner Pharma Group’s Managed Access Programs (MAP) division and Proveca have agreed to launch a Managed Access Program for an oral formulation of glycopyrronium (Sialanar®) outside Europe and the USA. Sialanar is for the treatment of sialorrhea, or chronic drooling, in…

    Read More
  17. Hiring of Jonathan Bracey as Managing Director – UK

    For Immediate Release Contact: Joshua Cooper Tanner Pharma Group 704.552.8408 CHARLOTTE, N.C., December 1, 2015 – Tanner Pharma Group is pleased to announce the hiring of Jonathan Bracey as Managing Director – UK, effective 1 December, 2015. Mr. Bracey brings two decades of management experience, making him an optimal candidate in leading the recently…

    Read More
  18. Max Global Experience: Uganda

    Tanner Pharma Group is proud to serve as the title sponsor for The Max Foundation’s 2018 “Max Global Experience: Uganda,” an expedition to raise awareness and funds for increased cancer treatment access in Africa. In August, Banks Bourne, Founder & Chairman of Tanner Pharma Group / CEO of Bourne Partners, and Rob Keel, Director of…

    Read More

Tanner Pharma Group uses cookies on its website. By continuing to access this website you are agreeing to Tanner Pharma Group’s Data Privacy Policy. For more information, click here.